How Investors May Respond To Agios Pharmaceuticals (AGIO) Sickle Cell FDA Review

Simply Wall St.10-16

Agios Pharmaceuticals recently received an FDA priority review for its oral pyruvate kinase activator mitapivat in sickle cell disease, with a regulatory decision expected by November 1 and potential ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2675561958?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","is_english":true,"pubTime":"2026-10-16 14:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2675561958","market":"sg","top_or_hot":-1,"title":"How Investors May Respond To Agios Pharmaceuticals (AGIO) Sickle Cell FDA Review","media":"Simply Wall St.","content":"<div>\n<p>Agios Pharmaceuticals recently received an FDA priority review for its oral pyruvate kinase activator mitapivat in sickle cell disease, with a regulatory decision expected by November 1 and potential ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/how-investors-may-respond-to-agios-pharmaceuticals-agio-sick\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors May Respond To Agios Pharmaceuticals (AGIO) Sickle Cell FDA Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors May Respond To Agios Pharmaceuticals (AGIO) Sickle Cell FDA Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-16 14:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/how-investors-may-respond-to-agios-pharmaceuticals-agio-sick><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Agios Pharmaceuticals recently received an FDA priority review for its oral pyruvate kinase activator mitapivat in sickle cell disease, with a regulatory decision expected by November 1 and potential ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/how-investors-may-respond-to-agios-pharmaceuticals-agio-sick\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4211","symbol_name":"区域性银行","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/how-investors-may-respond-to-agios-pharmaceuticals-agio-sick","article_id":"2675561958","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/how-investors-may-respond-to-agios-pharmaceuticals-agio-sick","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2675561958","pubTimestamp":1792132400,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Agios Pharmaceuticals recently received an FDA priority review for its oral pyruvate kinase activator mitapivat in sickle cell disease, with a regulatory decision expected by November 1 and potential to extend use beyond its current indications.\nThe review highlights how Agios is trying to widen its rare disease footprint by reusing an existing medicine in a new, genetically defined patient group. This could reshape the mix of revenue sources if the therapy reaches this broader...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4211":"区域性银行","BK4588":"碎股","LABU":"三倍做多标普生物-Direxion","AGIO":"Agios Pharmaceuticals, Inc.","BK4585":"ETF&股票定投概念","ISBC":"投资者银行","BK4139":"生物科技"},"translate_title":"投资者如何应对 Agios Pharmaceuticals (AGIO) 镰状细胞 FDA 审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1.5,"AGIO":1.5,"LABU":1.5},"content_text":"Agios Pharmaceuticals recently received an FDA priority review for its oral pyruvate kinase activator mitapivat in sickle cell disease, with a regulatory decision expected by November 1 and potential to extend use beyond its current indications. The review highlights how Agios is trying to widen its rare disease footprint by reusing an existing medicine in a new, genetically defined patient group. This could reshape the mix of revenue sources if the therapy reaches this broader population. We will look at how Agios Pharmaceuticals' investment narrative shifts as mitapivat's sickle cell priority review tests its concentration risk.  Scan beyond Agios Pharmaceuticals and line up other rare disease and specialty biopharma plays with resilient balance sheets using our curated list of solid balance sheet and fundamentals (25 results). AdvertisementAgios Pharmaceuticals Investment Narrative Recap To own Agios Pharmaceuticals, you need to be comfortable with a rare disease specialist that is still loss making, heavily tied to one molecule, and spending aggressively on development and commercialization. The big belief is that PYRUKYND and follow on pyruvate kinase activators can support a much larger hematology franchise over time, even as near term profitability remains out of reach. The priority review for mitapivat in sickle cell disease crystallizes the near term story. It concentrates execution risk around a single regulatory decision while R&D and SG&A remain high. If mitapivat does not secure broad, usable labeling, the main short term catalyst turns into the clearest business risk. Among recent developments, the priority FDA review of oral mitapivat in sickle cell disease is the announcement that matters most for this setup. It directly stress tests Agios Pharmaceuticals' dependence on extending PYRUKYND into new genetically defined groups after initial approval in pyruvate kinase deficiency. Your focus now is on three operational questions. First, whether the review outcome supports real world adoption without onerous safety monitoring. Second, how effectively Agios builds access and reimbursement in a new chronic population. Third, whether management can keep cash burn aligned with progress while the broader pipeline, including thalassemia and pediatric programs, remains in investment mode. Agios Pharmaceuticals' story assumes annual revenue growth of 70.2% and points to earnings shifting from a loss of $411.3 million today to a forecast of $82.4 million by 2029, a swing of about $493.7 million, with analysts expecting revenues of $485.0 million in the same year. Uncover why Agios Pharmaceuticals' fair value points to a 36% potential upside to its current price, which could narrow quickly if sentiment shifts. NasdaqGS:AGIO 1-Year Stock Price Chart Exploring Other Perspectives One alternate view on Agios Pharmaceuticals leans heavily on pricing pressure as the key risk. The most cautious analysts were modeling 2029 revenue of about $339.0 million and earnings of $64.1 million, which is well below the consensus figures. Those projections were set before this sickle cell priority review, so opinions may change as new information becomes available. Explore another Agios Pharmaceuticals fair value estimate, including one that suggests it could be worth just $44.00! Decide For Yourself Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis and judgment.  A great starting point for your Agios Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. See our latest analysis for Agios Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Agios Pharmaceuticals' overall financial health at a glance.  Looking For More Investment Ideas Beyond Agios Pharmaceuticals? Once the Agios Pharmaceuticals story is on your radar, it helps to compare it with other potential opportunities so you can see where it truly fits in your portfolio. Use the Simply Wall St Screener to quickly surface stocks that match different styles and risk appetites, then review them side by side with your current watchlist.  If you want potential upside without ignoring quality, start with a focused set of 33 high quality undervalued stocks that combine fundamentals with appealing valuations. For investors who care most about resilience and the ability to sleep at night, filter for companies on our 32 resilient stocks with low risk scores and see which ones align with your comfort zone. If income is your priority, focus on cash return opportunities by reviewing our curated 8 dividend fortresses that offer yields of 5% or more.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2675561958","isCrawlerRequest":true}